These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36828412)

  • 1. High Plasma Levels of Fibroblast Growth Factor 23 Are Associated with Increased Risk of COVID-19 in End-Stage Renal Disease Patients on Hemodialysis: Results of a Prospective Cohort.
    Toro L; Michea L; Parra-Lucares A; Mendez-Valdes G; Villa E; Bravo I; Pumarino C; Ayala P; Sanhueza ME; Torres R; Elgueta L; Chavez S; Rojas V; Alvo M
    Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast Growth Factor 23 Predicts Mortality and End-Stage Renal Disease in a Canadian Asian Population with Chronic Kidney Disease.
    Jialal I; Camacho F; Nathoo B; Tam P; Pahwa R; Wu GG
    Nephron; 2017; 137(3):190-196. PubMed ID: 28743129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 23 (FGF23) level is associated with ultrafiltration rate in patients on hemodialysis.
    Nishizawa Y; Hosoda Y; Horimoto A; Omae K; Ito K; Higuchi C; Sakura H; Nitta K; Ogawa T
    Heart Vessels; 2021 Mar; 36(3):414-423. PubMed ID: 33000285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study.
    Jovanovich A; You Z; Isakova T; Nowak K; Cheung A; Wolf M; Chonchol M; Kendrick J
    Am J Nephrol; 2019; 49(4):263-270. PubMed ID: 30820005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
    Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
    Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.
    Sugimoto H; Ogawa T; Iwabuchi Y; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):99-106. PubMed ID: 23355029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.
    Shimada T; Urakawa I; Isakova T; Yamazaki Y; Epstein M; Wesseling-Perry K; Wolf M; Salusky IB; Jüppner H
    J Clin Endocrinol Metab; 2010 Feb; 95(2):578-85. PubMed ID: 19965919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.
    Scialla JJ; Parekh RS; Eustace JA; Astor BC; Plantinga L; Jaar BG; Shafi T; Coresh J; Powe NR; Melamed ML
    Am J Nephrol; 2015; 42(1):25-34. PubMed ID: 26287973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.
    Ashikaga E; Honda H; Suzuki H; Hosaka N; Hirai Y; Sanada D; Nakamura M; Nagai H; Matsumoto K; Kato N; Mukai M; Watanabe M; Takahashi K; Shishido K; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):315-22. PubMed ID: 20609185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.
    Hsu HJ; Wu MS
    Am J Med Sci; 2009 Feb; 337(2):116-22. PubMed ID: 19214027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
    Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
    PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients.
    Takashi Y; Wakino S; Minakuchi H; Ishizu M; Kuroda A; Shima H; Tashiro M; Miya K; Okada K; Minakuchi J; Kawashima S; Matsuhisa M; Matsumoto T; Fukumoto S
    J Bone Miner Metab; 2020 Jan; 38(1):70-77. PubMed ID: 31420749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis.
    Zaritsky J; Rastogi A; Fischmann G; Yan J; Kleinman K; Chow G; Gales B; Salusky IB; Wesseling-Perry K
    Nephrol Dial Transplant; 2014 Feb; 29(2):437-41. PubMed ID: 24009282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.
    Isakova T; Xie H; Barchi-Chung A; Vargas G; Sowden N; Houston J; Wahl P; Lundquist A; Epstein M; Smith K; Contreras G; Ortega L; Lenz O; Briones P; Egbert P; Ikizler TA; Jueppner H; Wolf M
    Clin J Am Soc Nephrol; 2011 Nov; 6(11):2688-95. PubMed ID: 21903990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23.
    Montford JR; Chonchol M; Cheung AK; Kaufman JS; Greene T; Roberts WL; Smits G; Kendrick J;
    Am J Nephrol; 2013; 37(3):183-90. PubMed ID: 23428834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19: mortality rates of patients on hemodialysis and peritoneal dialysis.
    Yavuz D; Karagöz Özen DS; Demirağ MD
    Int Urol Nephrol; 2022 Oct; 54(10):2713-2718. PubMed ID: 35381932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy.
    Park JS; Minn D; Hong S; Jeong S; Kim S; Lee CH; Kim B
    J Korean Med Sci; 2022 Jun; 37(23):e180. PubMed ID: 35698835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.